Amid Legal Risks, This Company Is Still Rated a Buy
When investors look for stocks riding the aging of America, they might look at hospital chains, pharmacy benefit managers, or dividend-paying healthcare REITs.
Wall Street Analysts See a 25.73% Upside in PACS Group, Inc. (PACS): Can the Stock Really Move This High?
The consensus price target hints at a 25.7% upside potential for PACS Group, Inc. (PACS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PACS Group Q2 Earnings Call Highlights
PACS Group NYSE: PACS reported second-quarter 2026 revenue growth of 9.1% and adjusted EBITDA growth of 25% from a year earlier, citing higher occupancy, improved skilled nursing patient mix and continued progress across acquired facilities as they mature within its operating model.
PACS Group, Inc. (PACS) Q2 2026 Earnings Call Transcript
PACS Group, Inc. (PACS) Q2 2026 Earnings Call Transcript
PACS Group, Inc. (PACS) Surpasses Q2 Earnings and Revenue Estimates
PACS Group, Inc. (PACS) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.31 per share a year ago.
PACS or ALHC: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with PACS Group, Inc. (PACS) and Alignment Healthcare (ALHC). But which of these two companies is the best option for those looking for undervalued stocks?
PACS or ALHC: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both PACS Group, Inc. (PACS) and Alignment Healthcare (ALHC). But which of these two stocks presents investors with the better value opportunity right now?
PACS Group Q1 Earnings Call Highlights
PACS Group NYSE: PACS reported a strong start to 2026, with executives citing higher occupancy, improved skilled mix and continued progress integrating acquired facilities as drivers of first-quarter performance.
PACS Group: Strong Comeback That's Backed By Improving Fundamentals
PACS Group (PACS) is reaffirmed as a 'Buy' for long-term investors, following a 257% rebound from oversold lows. PACS demonstrates robust credit health with $795M liquidity, 0.1x net leverage, and strong interest coverage, supporting aggressive organic and acquisition-driven growth. Guidance for FY26 includes 8% revenue growth and 22% adjusted EBITDA growth, with margin expansion driven by facility maturation and industry consolidation opportunities.
PACS Group, Inc. (PACS) Q1 2026 Earnings Call Transcript
PACS Group, Inc. (PACS) Q1 2026 Earnings Call Transcript
PACS Group, Inc. (PACS) Q1 Earnings and Revenues Surpass Estimates
PACS Group, Inc. (PACS) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.17 per share a year ago.
PACS vs. MEDP: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of PACS Group, Inc. (PACS) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
